NCT01009970

Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

Multicenter Study of Phase II With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet ®), Vincristine, Prednisone, (R-COMP) in Non-Hodgkin's Lymphoma Diffuse Large B Cell in Cardiopathic Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Fondazione Italiana Linfomi - ETS · Academic / Other
• Sex: All
• Age: 18 Months
• Healthy volunteers: Not accepted

Summary

This is a multicenter study phase II, open-label for cardiopathic patients affected by Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular. The purpose is to study the feasibility of R-COMP in this cohort of patients.

Conditions

• Diffuse Large B-Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Rituximab	375 mg/m2 day 1
DRUG	Cyclophosphamide	750 mg/m2 day 2
DRUG	Vincristine	1,4 mg/m2 (max 2 mg) day 2
DRUG	Prednisone	40 mg/m2 day 2-6
DRUG	Doxorubicin	50 mg/m2 day 2

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-05-01
• Completion: 2012-05-01
• First posted: 2009-11-09
• Last updated: 2011-10-13

Locations

32 sites across 1 country: Italy